Pharma Journalist -

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option…
Read More...

Ionis Pharmaceuticals, Inc. announced that Ionis and AstraZeneca’s WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary…
Read More...

As part of its ongoing efforts to ensure patients who need Wegovy (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can access it, Novo Nordisk launched NovoCare…
Read More...

Astellas Pharma Inc. and YASKAWA Electric Corporation signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform…
Read More...

Plus Therapeutics, Inc. announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of…
Read More...

Gain insights into the cutting-edge innovation in in vivo and in vitro tumour modelling, discover strategies to de-risk your studies, and learn how to refine your drug development…
Read More...

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, announced positive topline results from its ALLEVIATE-2 Phase 3 pivotal clinical trial evaluating cebranopadol,…
Read More...

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to…
Read More...

TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the…
Read More...

AbbVie and Gubra A/S, a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, announced a license…
Read More...